Oxbryta (Voxelotor) Patent Expiration, LOE Window & CMS Spending

Oxbryta (Voxelotor) by Pfizer: FDA Orange Book core substance LOE 2035-02-06 (last listed 2037-10-12), 0 AB generics, $195.8M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN213137 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-02-06
Last Listed Patent or Exclusivity Date2037-10-12
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$195.8M
2024 Medicare Part D Spend$77.2M
2024 Medicaid Spend$118.6M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 20.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.